Compare LyondellBasell Industries NV (LYB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Nuwellis Inc — how do they compare? LyondellBasell Industries NV trades at $60.13 (market cap $19.49B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: LyondellBasell Industries NV is far larger — about 8859.1× Nuwellis Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and Nuwellis Inc for 26 Days on average.
| LYB | NUWE | |
|---|---|---|
Market Cap | $19.49B | $2.20M |
Volume | 6,033,396 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $146.65 |
52-Week Low | $42.28 | $0.68 |
Typical Hold Time | 87 Days | 26 Days |
Enterprise Value | $31.08B | -$1.52M |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.03, up 2.63% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $4.30 beating expectations of $3.44, but faces fundamental challenges with negative net income margin of -1.13% and declining revenue from $50.5B in 2022 to $30.2B in 2025. Analyst consensus remains divided with 45% buy and 45% hold ratings, targeting $69.38 average price.
LYB shows operational resilience with improving cash flow projections for 2026, but faces significant headwinds from declining profitability and competitive pressures. The dividend yield remains attractive but sustainability concerns persist given the negative earnings trend. Near-term upside exists if operational improvements continue, though investors should monitor debt levels and chemical sector cyclicality.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
